Current medical abortion care

Current Women's Health Reports

Volumn 3, Issue 6, 2003, Pages 461-469

  Creinin, Mitchell D ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; GEMEPROST; METHOTREXATE; MIFEPRISTONE; MISOPROSTOL; NORETHISTERONE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1 DERIVATIVE; SULPROSTONE; ABORTIVE AGENT; POSTCOITUS CONTRACEPTIVE AGENT;

ADRENAL INSUFFICIENCY; AREA UNDER THE CURVE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CLINICAL TRIAL; CONGENITAL MALFORMATION; COST CONTROL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ECTOPIC PREGNANCY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ACCESS; HOME CARE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MUSCLE CRAMP; NAUSEA; OUTCOMES RESEARCH; PAIN; PATIENT CARE; PATIENT COUNSELING; PORPHYRIA; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; REVIEW; SAFETY; SECOND TRIMESTER ABORTION; SURGICAL TECHNIQUE; SYNCOPE; TRANSVAGINAL ECHOGRAPHY; UTERUS BLEEDING; VOMITING; ADOLESCENT; ADULT; INDUCED ABORTION; METHODOLOGY; PATIENT ATTITUDE; PATIENT EDUCATION; PREGNANCY; SEXUAL BEHAVIOR; TREATMENT OUTCOME; UNITED STATES; WOMEN'S HEALTH;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADOLESCENT; ADULT; CONTRACEPTIVES, POSTCOITAL, SYNTHETIC; FEMALE; HUMANS; MIFEPRISTONE; MISOPROSTOL; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT EDUCATION; PREGNANCY; SEXUAL BEHAVIOR; TREATMENT OUTCOME; UNITED STATES; WOMEN'S HEALTH;

EID: 1542547942     PISSN: 15345874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Creinin MD: Medical abortion regimens: historical context and overview: Am J Obstet Gynecol 2000, 183:S3-S9.
2. Winikoff B, Ellertson C, Clark S: Analysis of failure in medical abortion. Contraception 1996, 54:323-327.
3. Wiebe E, Dunn S, Guilbert E, et al.: Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol 2002, 99:813-819.
4. Jain JK, Dutton C, Harwood B, et al.: A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 2002, 17:1477-1482.
5. Gravanis A, Schaison G, George M, et al.: Endometrial and pituitary responses to the steroidal anti-progestin RU 486 in post-menopausal women. J Clin Endocrinol Metab 1984, 60:156-163.
6. Kelly RW, Healy DL, Cameron MJ, et al.: RU 486 stimulation of PGF2a production in isolated endometrial cells in short term culture. In The Antiprogestin Steroid RU 486 and Human Fertility Control. Edited by Beaulieu EE, Siegel S. New York: Plenum; 1985:259-262.
7. Herrmann WL, Schindler AM, Wyss R, Bischoff P: Effects of the antiprogesterone RU 486 in early pregnancy and during the menstrual cycle. In The Antiprogestin Steroid RU 486 and Human Fertility Control. Edited by Beaulieu EE, Siegel S. New York: Plenum; 1985:179-98.
8. Shi Y-e, Ye Z-h, He C-h, et al.: Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 1993, 48:133-149.
9. Ledger WL, Sweeting VM, Hillier H, Baird DT: Inhibition of ovulation by low-dose mifepristone (RU 486). Human Reprod 1992, 7:945-950.
10. Batista MC, Cartledge TP, Zellmer AW, et al.: The antiprogestin RU486 delays the midcycle gonadotropin surge and ovulation in gonadotropin-releasing hormone-induced cycles. Fertil Steril 1994, 62:28-34.
11. Lähteenmäki P, Heikinheimo O, Croxatto H, et al.: Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 1987, 27:859-863.
12. Heikinheimo O: Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. J Steroid Biochem 1989, 32:21-25.
13. Heikinheimo O, Lähteenmäki PLA, Koivunen E, et al.: Metabolism and serum binding of RU 486 in women after various single doses. Human Reprod 1987, 2:379-385.
14. Swahn ML, Cekan S, Wang G, et al.: Pharmacokinetic and clinical studies of RU 486 for fertility regulation. In The Antiprogestin Steroid RU 486 and Human Fertility Control. Edited by Beaulieu EE, Siegel S. New York: Plenum; 1985:249-258.
15. Bygdeman M, Swahn M-L: Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception 1985, 32:45-51.
16. Aubény E, Baulieu EE: Activité contragestive de l'association an RU 486 d'une prostaglandine active par voie orale. C R Acad Sci III 1991, 312:539-545.
17. Norman JE, Thong KJ, Baird DT: Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991, 338:1233-1236.
18. Zieman M, Fong SK, Benowitz NL, et al.: Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997, 90:88-92.
19. Silvestre L, Dubois C, Renault M, et al.: Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue: a large-scale French experience. N Engl J Med 1990, 322:645-648.
20. Ulmann A, Silvestre L, Chemama L, et al.: Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue: study in 16,369 women. Acta Obstet Gynecol Scand 1992, 71:278-283.
21. Peyron R, Aubény E, Targosz V, et al.: Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993, 328:1509-1513.
22. Aubény E, Peyron R, Turpin CL, et al.: Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone (RU486) and increasing doses of misoprostol. Int J Fertil Menopausal Stud 1995, 40(Suppl2):85-91.
23. Spitz IM, Bardin CW, Benton L, Robbins A: Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998, 338:1241-1247.
24. Aubény E: A two-stage increase in the dose of misoprostol improves the efficacy of medical abortion with mifepristone and prostaglandins [letter]. Eur J Contracept Reprod Health Care 2001, 6:54-55.
25. El-Rafaey H, Rajasekar D, Abdalla M, et al.: Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995, 332:983-987.
26. Jones RK, Henshaw SK: Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect Sex Reprod Health 2002, 34:154-161.
27. World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation: Termination of pregnancy with reduced doses of mifepristone. BMJ 1993, 307:532-537.
28. McKinley C, Thong KJ, Baird DT: The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 1993, 8:1502-1505.
29. World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation: Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG 2000, 107:524-530.
30. Ashok P, Penney G, Flett G, Templeton A: An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998, 13:2962-2965.
31. Schaff EA, Eisinger SH, Stadalius LS, et al.: Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 1999, 59:1-6.
32. Schaff EA, Fielding SL, Eisinger SH, et al.: Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000, 61:41-6.
33. Tang OS, Ho PC: Pilot study on the use of sublingual misoprostol for medical abortion. Contraception 2001, 64:315-317.
34. Tang OS, Xu J, Cheng L, et al.: Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. Hum Reprod 2002, 17:1738-1740.
35. El-Rafaey H: Early induction of abortion by a combination of oral mifepristone and misoprostol administered by the vaginal route. Contraception 1994, 49:111-114.
36. Bartley J, Brown A, Elton R, Baird DT: Double-blind randomized trial of mifepristone in combination with vaginal geme-prost of misoprostol for induction of abortion up to 63 days gestation. Hum Reprod 2001, 16:2098-2102.
37. Schaff EA, Fielding SL, Westhoff C: Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception 2001, 64:81-85.
38. Schaff EA, Stadalius LS, Eisinger SH, Franks P: Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract 1997, 44:353-360.
39. Schaff EA, Fielding SL, Westhoff C, et al.: Randomized trial of vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion (<56 days gestation). JAMA 2000, 284:1948-1953.
40. Pymar HC, Creinin MD, Schwartz JL: Mifepristone followed on the same day by vaginal misoprostol for early abortion. Contraception 2001, 64:87-92.
41. Fox MC, Creinin MD, Harwood B: Mifepristone and vaginal misoprostol on the same day for abortion from 50 to 63 days' gestation. Contraception 2002, 66:225-229.
42. Henshaw RC, Naji SA, Russell IT, Templeton AA: Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ 1993, 307:714-717.
43. Westhoff C, Picardo L, Morrow E: Quality of life following early medical or surgical abortion. Contraception 2003, 67:41-47.
44. Tang GW, Lau OWK, Yip P: Further acceptability evaluation of RU 486 and ONO 802 as abortifacient agents in a Chinese population. Contraception 1993, 48:267-276.
45. Creinin MD, Park M: Acceptability of medical abortion with methotrexate and misoprostol. Contraception 1995, 52:41-44.
46. Creinin MD, Burke AE: Methotrexate and misoprostol for early abortion: a multicenter trial. Acceptability. Contraception 1996, 54:19-22.
47. Cameron ST, Glasier AF, Logan J, et al.: Impact of the introduction of new medical methods on therapeutic abortions at the Royal Infirmary of Edinburgh. Br J Obstet Gynaecol 1996, 103:1222-1229.
48. Winikoff B, Ellertson C, Elul B, Sivin I: Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol: results of a large multicenter trial in the United States. Arch Fam Med 1998, 7:360-366.
49. Ngoc NT, Winikoff B, Clark S, et al.: Safety, efficacy and acceptability of mifepristone-misoprostol abortion in Vietnam. Int Fam Plann Perspect 1999, 25:10-14, 33.
50. Winikoff B, Sivin I, Coyaji KJ, et al.: The acceptability of medical abortion in China, Cuba and India. Int Fam Plann Perspect 1997, 23:73-78, 89.
51. Wiebe ER: Abortion induced with methotrexate and misoprostol: a comparison of various protocols. Contraception 1997, 55:159-163.
52. Goujard J: Mifépristone, risque téraogenes. L'interruption de grossesse depuis in loi veil. Flammarion 1992, 55-57.
53. Fonseca W, Alencar AJC, Mota FSB, Coelho HLL: Misoprostol and congenital malformations. Lancet 1991, 338:56.
54. Gonzalez CH, Vargas R, Perez AB, et al.: Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet 1993, 47:59-64.
55. Schuler L, Pastuszak A, Sanseverino TV, et al.: Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999, 13:147-151.
56. Urquhart DR, Templeton A: Reduced risk of isoimmunisation in medical abortion [letter]. Lancet 1990, 335:914.
57. Creinin MD, Shulman T: Effect of non-steroidal anti-inflammatory drugs on the action of misoprostol in a regimen for early abortion. Contraception 1997, 56:165-168.
58. Creinin MD, Aubeny E: Medical abortion in early pregnancy. In A Clinician's Guide to Medical and Surgical Abortion. Edited by Paul M, Lichtenberg ES, Borgatta L, et al. New York: Churchill Livingstone; 1999:91-106.
59. Harwood B, Meckstroth KR, Mishell DR, Jain JK: Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. Contraception 2001, 63:255-256.
60. Thong KJ, Baird DT: Induction of abortion with mifepristone and misoprostol in early pregnancy. Br J Obstet Gynaecol 1992, 99:1004-1007.
61. Davis A, Westhoff C, De Nonno L: Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. JAMWA 2000, 55:141-144.
62. Tang OS, Gao PP, Cheng L, et al.: A randomized double-blind placebo-controlled study to assess the effect of OC pills on the outcome of medical abortion with mifepristone and misoprostol. Hum Reprod 1999, 14:722-725.
63. Tang OS, Xu J, Cheng L, et al.: The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol a randomized placebo controlled trial. Hum Reprod 2002, 17:99-102.
64. Creinin MD, Potter C, Holovanisin M, et al.: Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion. Am J Obstet Gynecol 2003, 188:664-669.